Top

Published in:

Open Access 01-12-2013 | Research

Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases −2 expression in ovarian carcinoma

Authors: Liping Wang, Xiangshu Jin, Dongjing Lin, Zhijing Liu, Xiaowei Zhang, Yan Lu, Yuanyuan Liu, Min Wang, Minlan Yang, Jiuxia Li, Chengshi Quan

Published in: Diagnostic Pathology | Issue 1/2013

Abstract

Background

Tight junctions (TJs) are mainly composed of claudins, occludin, and tight junction adhesion molecules (JAM). The invasive and metastatic phenotype of highly invasive cancer cells has been related to abnormal structure and function of TJs, and with expression of activated matrix metalloproteinases (MMPs). The relevance of these mechanisms responsible for the invasion and metastasis of ovarian carcinoma is unclear. Similarly, it is not known if the expression of claudin-6, occludin and MMP2 is related with the clinical properties of these tumors.

Methods

Expression of claudin-6, occludin, and MMP2 was detected in samples of human ovarian cancer tissues by immunohistochemistry and correlated with the clinical properties of the tumors.

Results

The positive expression rates of claudin-6 and MMP-2 were higher in ovarian papillary serous carcinomas than n ovarian serous adenomas (P < 0.05). There were no differences in the expression of occludin (P > 0.05). The expression of claudin-6 and occludin in ovarian cancer was not correlated with patient age, pathological grade, clinical stage, and metastasis (P > 0.05). MMP-2 expression was enhanced with increased clinical stage and metastasis (P < 0.05), but was unrelated to patient age or tumor grade (P > 0.05). There were no apparent correlations between expression of claudin-6, occludin and MMP-2 in ovarian cancer tissue (P > 0.05).

Conclusions

Our data suggest, for the first time, that the claudin-6 and MMP-2 are up-regulated in ovarian papillary serous carcinomas, MMP-2 expression was enhanced with increased clinical stage and metastasis. Claudin-6 and MMP-2 may play a positive role in the invasion and metastasis of ovarian cancer.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1775628454106511.

Available only for authorised users

Egeberg DL, Lethan M, Manguso R, Schneider L, Awan A, Jorgensen TS, Byskov AG, Pedersen LB, Christensen ST: Primary cilia and aberrant cell signaling in epithelial ovarian cancer. Cilia. 2012, 1: 15-10.1186/2046-2530-1-15.PubMedCentralCrossRefPubMed

Waldemarson S, Krogh M, Alaiya A, Kirik U, Schedvins K, Auer G, Hansson KM, Ossola R, Aebersold R, Lee H, et al.: Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res. 2012, 11: 2876-2889. 10.1021/pr201258q.CrossRefPubMed

Itoh M, Bissell MJ: The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia. 2003, 8: 449-462.PubMedCentralCrossRefPubMed

Gonzalez-Mariscal L, Lechuga S, Garay E: Role of tight junctions in cell proliferation and cancer. Prog Histochem Cytochem. 2007, 42: 1-57. 10.1016/j.proghi.2007.01.001.CrossRefPubMed

Agarwal R, D’Souza T, Morin PJ: Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005, 65: 7378-7385. 10.1158/0008-5472.CAN-05-1036.CrossRefPubMed

Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, Sukumar S: Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol. 2004, 164: 1627-1633. 10.1016/S0002-9440(10)63721-2.PubMedCentralCrossRefPubMed

Nichols LS, Ashfaq R, Iacobuzio-Donahue CA: Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol. 2004, 121: 226-230. 10.1309/K144PHVDDUPDD401.CrossRefPubMed

Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, Moss SF: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol. 2005, 36: 886-892. 10.1016/j.humpath.2005.05.019.CrossRefPubMed

de Oliveira SS, de Oliveira IM, De Souza W, Morgado-Diaz JA: Claudins upregulation in human colorectal cancer. FEBS Lett. 2005, 579: 6179-6185. 10.1016/j.febslet.2005.09.091.CrossRefPubMed

10.

Martin TA, Jiang WG: Tight junctions and their role in cancer metastasis. Histol Histopathol. 2001, 16: 1183-1195.PubMed

11.

Miyamori H, Takino T, Kobayashi Y, Tokai H, Itoh Y, Seiki M, Sato H: Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem. 2001, 276: 28204-28211. 10.1074/jbc.M103083200.CrossRefPubMed

12.

Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T: Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res. 2006, 66: 5251-5257. 10.1158/0008-5472.CAN-05-4478.CrossRefPubMed

13.

Lu Z, Lu N, Li C, Li F, Zhao K, Lin B, Guo Q: Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett. 2012, 209: 211-220. 10.1016/j.toxlet.2011.12.022.CrossRefPubMed

14.

Sims JD, McCready J, Jay DG: Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One. 2011, 6: e18848-10.1371/journal.pone.0018848.PubMedCentralCrossRefPubMed

15.

Zeng ZS, Cohen AM, Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999, 20: 749-755. 10.1093/carcin/20.5.749.CrossRefPubMed

16.

Lippoldt A, Liebner S, Andbjer B, Kalbacher H, Wolburg H, Haller H, Fuxe K: Organization of choroid plexus epithelial and endothelial cell tight junctions and regulation of claudin-1, -2 and −5 expression by protein kinase C. Neuroreport. 2000, 11: 1427-1431. 10.1097/00001756-200005150-00015.CrossRefPubMed

17.

Martin TA, Jiang WG: Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009, 1788: 872-891. 10.1016/j.bbamem.2008.11.005.CrossRefPubMed

18.

Miyoshi J, Takai Y: Molecular perspective on tight-junction assembly and epithelial polarity. Adv Drug Deliv Rev. 2005, 57: 815-855. 10.1016/j.addr.2005.01.008.CrossRefPubMed

19.

Pan XY, Wang B, Che YC, Weng ZP, Dai HY, Peng W: Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int J Gynecol Cancer. 2007, 17: 233-241. 10.1111/j.1525-1438.2006.00748.x.CrossRefPubMed

20.

Long H, Crean CD, Lee WH, Cummings OW, Gabig TG: Expression of clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001, 61: 7878-7881.PubMed

21.

Banan A, Zhang LJ, Shaikh M, Fields JZ, Farhadi A, Keshavarzian A: Theta-isoform of PKC is required for alterations in cytoskeletal dynamics and barrier permeability in intestinal epithelium: a novel function for PKC-theta. Am J Physiol Cell Physiol. 2004, 287: C218-C234. 10.1152/ajpcell.00575.2003.CrossRefPubMed

22.

Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C: Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004, 22: 3531-3539. 10.1200/JCO.2004.08.127.CrossRefPubMed

23.

Rangel LB, Agarwal R, D’Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003, 9: 2567-2575.PubMed

24.

Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE: Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol. 2005, 18: 511-518. 10.1038/modpathol.3800301.CrossRefPubMed

25.

Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S: Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene. 2003, 22: 2021-2033. 10.1038/sj.onc.1206199.CrossRefPubMed

26.

Wu Q, Liu Y, Ren Y, Xu X, Yu L, Li Y, Quan C: Tight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinoma. Eur J Cancer Prev. 2010, 19: 186-194. 10.1097/CEJ.0b013e328337210e.CrossRefPubMed

27.

Xu X, Jin H, Liu Y, Liu L, Wu Q, Guo Y, Yu L, Liu Z, Zhang T, Zhang X, et al.: The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas. Diagn Pathol. 2012, 7: 33-10.1186/1746-1596-7-33.PubMedCentralCrossRefPubMed

28.

Lin Z, Zhang X, Liu Z, Liu Q, Wang L, Lu Y, Liu Y, Wang M, Yang M, Jin X, Quan C: The distinct expression patterns of claudin-2, -6, and −11 between human gastric neoplasms and adjacent non-neoplastic tissues. Diagn Pathol. 2013, 8: 133-10.1186/1746-1596-8-133.PubMedCentralCrossRefPubMed

29.

Ando-Akatsuka Y, Saitou M, Hirase T, Kishi M, Sakakibara A, Itoh M, Yonemura S, Furuse M, Tsukita S: Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues. J Cell Biol. 1996, 133: 43-47. 10.1083/jcb.133.1.43.CrossRefPubMed

30.

Orban E, Szabo E, Lotz G, Kupcsulik P, Paska C, Schaff Z, Kiss A: Different expression of occludin and ZO-1 in primary and metastatic liver tumors. Pathol Oncol Res. 2008, 14: 299-306. 10.1007/s12253-008-9031-2.CrossRefPubMed

31.

Tobioka H, Isomura H, Kokai Y, Tokunaga Y, Yamaguchi J, Sawada N: Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol. 2004, 35: 159-164. 10.1016/j.humpath.2003.09.013.CrossRefPubMed

32.

Busch C, Hanssen TA, Wagener C, OBrink B: Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol. 2002, 33: 290-298. 10.1053/hupa.2002.32218.CrossRefPubMed

33.

Osanai M, Murata M, Nishikiori N, Chiba H, Kojima T, Sawada N: Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res. 2006, 66: 9125-9133. 10.1158/0008-5472.CAN-06-1864.CrossRefPubMed

34.

Rouach N, Pebay A, Meme W, Cordier J, Ezan P, Etienne E, Giaume C, Tence M: S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci. 2006, 23: 1453-1464. 10.1111/j.1460-9568.2006.04671.x.CrossRefPubMed

35.

Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol. 1992, 16: 500-507. 10.1097/00000478-199205000-00009.CrossRefPubMed

36.

van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.CrossRefPubMed

37.

Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature. 2005, 436: 518-524. 10.1038/nature03799.PubMedCentralCrossRefPubMed

38.

Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kauppila A, Tryggvason K: Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest. 1993, 69: 312-321.PubMed

39.

Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ: Gelatinase (MMP-2 and −9) expression in gastrointestinal malignancy. Br J Cancer. 1998, 78: 1495-1502. 10.1038/bjc.1998.712.PubMedCentralCrossRefPubMed

40.

Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999, 43 (Suppl): S42-S51.CrossRefPubMed

41.

Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997, 277: 225-228. 10.1126/science.277.5323.225.CrossRefPubMed

42.

Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, et al.: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004, 88: 75-85. 10.1007/s10549-004-1200-8.CrossRefPubMed

43.

Katoh T, Yasuda M, Hasegawa K, Kozawa E, Maniwa J, Sasano H: Estrogen-producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases. Diagn Pathol. 2012, 7: 164-10.1186/1746-1596-7-164.PubMedCentralCrossRefPubMed

44.

Asher V, Khan R, Warren A, Shaw R, Schalkwyk GV, Bali A, Sowter HM: The eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010, 5: 78-10.1186/1746-1596-5-78.PubMedCentralCrossRefPubMed

45.

Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A: Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol. 2012, 7: 124-10.1186/1746-1596-7-124.PubMedCentralCrossRefPubMed

46.

Sundov D, Caric A, Mrklic I, Gugic D, Capkun V, Hofman ID, Mise BP, Tomic S: P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Diagn Pathol. 2013, 8: 21-10.1186/1746-1596-8-21.PubMedCentralCrossRefPubMed

Title: Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases −2 expression in ovarian carcinoma
Authors: Liping Wang
Xiangshu Jin
Dongjing Lin
Zhijing Liu
Xiaowei Zhang
Yan Lu
Yuanyuan Liu
Min Wang
Minlan Yang
Jiuxia Li
Chengshi Quan
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/1746-1596-8-190

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases −2 expression in ovarian carcinoma

Abstract

Background

Methods

Results

Conclusions

Virtual slides

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Virtual slides

Please log in to get access to this content

Other articles of this Issue 1/2013

Identification of genuine primary pulmonary NK cell lymphoma via clinicopathologic observation and clonality assay

The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer

Is mammary not otherwise specified-type sarcoma with CD10 expression a distinct entity? A rare case report with immunohistochemical and ultrastructural study

Endometrioid adenocarcinoma with simultaneous endocervical and intestinal-type mucinous differentiation: report of a rare phenomenon and the immunohistochemical profile

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population

RETRACTED ARTICLE: RNAi targeting CXCR4 inhibits proliferation and invasion of esophageal carcinoma cells